{"id":"luveris-increasing-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Luveris binds to LH receptors on theca cells in the ovary, promoting androgen production which is then converted to estrogen by granulosa cells. This hormone is used in combination with follicle-stimulating hormone (FSH) to support controlled ovarian hyperstimulation during fertility treatment. The increasing dose regimen allows titration to optimize follicle development while minimizing ovarian hyperstimulation syndrome risk.","oneSentence":"Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:44.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility in women undergoing assisted reproductive technology (ART) requiring ovarian stimulation"}]},"trialDetails":[{"nctId":"NCT04189133","phase":"PHASE2","title":"Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2022-01-19","conditions":"Acquired Hypogonadotropic Hypogonadism","enrollment":32},{"nctId":"NCT00889512","phase":"PHASE4","title":"The Luveris In Vitro Fertilization Trial","status":"TERMINATED","sponsor":"University Reproductive Associates","startDate":"2009-04","conditions":"Infertility, Hypothalamic Amenorrhea, Hyperprolactinemia","enrollment":14},{"nctId":"NCT02108223","phase":"PHASE4","title":"The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI","status":"COMPLETED","sponsor":"Sisli Hamidiye Etfal Training and Research Hospital","startDate":"2009-01","conditions":"Infertility","enrollment":137}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Luveris increasing dose","genericName":"Luveris increasing dose","companyName":"University Reproductive Associates","companyId":"university-reproductive-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology. Used for Infertility in women undergoing assisted reproductive technology (ART) requiring ovarian stimulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}